German health care and science group Merck has sealed a deal to bolster its cancer treatment portfolio with a US$3.9 billion ...

A bitter management shake-up. Angry public outbursts. A “narcissistic” pastor whose word is gospel. What in God’s name is ...

China rejected US trade overtures Thursday, demanding all tariffs be lifted and denying any progress in talks. "The US should ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

The deal will be funded with available cash and new debt. It is expected to be accretive to Merck’s earnings per share, adjusted for special items, in 2027, said a statement from the German ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

Halozyme (HALO) filed a patent infringement lawsuit against Merck (MRK) in U.S. District Court in New Jersey. Halozyme believes the ...

German health care and science group Merck has sealed a deal to bolster its cancer treatment portfolio with a $3.9-billion ...

(Reuters) -U.S. drugmaker Merck is investing $1 billion in a new Delaware plant to expand its domestic production as it prepares to deal with the looming impact from President Donald Trump's tariffs, ...